Amarin Corp Plc (AMRN)

[Jasbg]

Here is some thoughts from Yahoo post - thanks to David:
---------------------------------

David8 hours ago

Building on my earlier comment on the risk reward with Amarin, I also have a theory about which company might make a move on Amarin. Early on I thought PFE would be a logical choice but they are putting Lipitor into the new Mylan, and I don’t think that company will have an appetite for a new/large acquisition anytime soon. However, an even better prospect is Novartis. What they bring to the table is a huge European franchise coupled with worldwide presence. According to their own website, they have a strong interest in cardiovascular and especially cardio-metabolic diseases. They specifically talk about inflammation and cardiovascular disease. From what I can tell there is strong alignment with Amarin and Novartis product focus. Novartis has the financial capacity to absorb Amarin. And one more thing. Novartis owns Sandoz, one of the largest generics in the world. Let that sink in for a moment. I wish I had a perfect crystal ball, but I really believe Novartis is a logical if not the perfect acquirer of Amarin.

Having read something about Novatis and UK trial - i think the 'train may have already left' - for Vascepa as a CDV favorit - or then again 'maybe not' - what do others think of Davids thoughts on the subject ?

Novartis are 'ALL IN' in UK (500.000 people trials) New HQ in London.

https://www.novartis.co.uk/news/media-releases/uk-announced-global-centre-major-cardiovascular-trial-novartis-opens-new-hq

https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-three-pivotal-trials-showing-durable-and-potent-efficacy-inclisiran-investigational-first-class-sirna-cholesterol-lowering

Jasbg